Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
A panel of the Ministry of Health, Labor and Welfare (MHLW) on January 29 gave the final thumbs-up for a plan to add shingles vaccines to the national immunization program (NIP), beginning in FY2025. The NIP access will start on…
To read the full story
Related Article
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
May 25, 2023
- MHLW to Resume Discussions on Revising Basic Immunization Plan
March 27, 2023
REGULATORY
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
- Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…